ESC Congress 2015, London: hot lines truly hot?

2. The ALBATROSS (Aldosterone Lethal Effects Blockade in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up) trial failed to show that al-dosterone antagonists were beneficial to patients with myocardial infarction without heart failure. 3. The PRomPT (Post-Myocardial Infarction Remodelling Prevention Therapy) trial showed that peri-infarct pacing did not prevent left ventricular remodelling or improve functional, or clinical outcomes during 18 months of follow-up in patients with a large first myocardial infarction. 4. The OPTIDUAL (Optimal Duration of Dual Antiplate-let Therapy After Drug-eluting Stent Implantation) trial aimed to evaluate dual antiplatelet therapy (DAPT) for an additional 36 months among subjects who received a drug-eluting stent and were event-free at 12 months. The trial failed to reach primary outcome; however, extended duration of DAPT non-significantly reduced ischaemic events without increasing bleeding. 5. The ARTS-HF (Mineralocorticoid Receptor AnTagonist Study In Heart Failure) trial failed to show a reduction in NT-proBNP levels for finerenone versus eplerenone; however, secondary outcomes favoured finerenone. 6. The TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) trial showed that sitagliptin improves glycaemic control without increasing adverse cardiovascular events. Among diabetic subjects with documented cardiovascular disease, sitagliptin was non-inferior to placebo on the outcome of adverse cardiovas-cular events. 7. The ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) study evaluated treatment with lix-isenatide versus placebo in patients with type 2 diabetes presenting with an acute coronary syndrome. Although At the ESC Congress 2015 in London, six different Hot Line sessions were organised. The six topics were acute myo-cardial infarction, atrial fibrillation/pacing, diabetes/phar-macology, hypertension, heart failure, and coronary artery disease. Hot Line sessions are usually the main attraction of the ESC Congress as novel data are being presented for the first time [1]. Altogether 26 novel studies were presented during the six Hot Line sessions. All these Hot Line studies will be reported in detail in a special NHJ supplement that is added to this November edition of our journal. Therefore, the outcomes of all these trials will not be addressed here. The focus of this Comment is to briefly highlight those trials that had a negative (or neutral) outcome. Over the past years, trials with a negative outcome seem to outnumber trials with a positive outcome during the annual ESC Congresses [2, 3]. The following studies mentioned below had a negative outcome for their primary endpoints at the ESC Congress 2015 in …